10-Q: ReShape Lifesciences Faces Steep Revenue Decline

ReShape Lifesciences reported a significant revenue contraction and increased net losses, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Summary

• Revenue for the three months ended June 30, 2025, decreased by 36.8% to $1.242 million, down from $1.965 million in the prior year period.
• Year-to-date revenue for the six months ended June 30, 2025, contracted by 39.8% to $2.355 million, compared to $3.909 million in the same period of 2024.
• Gross profit for the three months ended June 30, 2025, was $0.599 million (48.2% of revenue), a 47.2% decrease from $1.134 million (57.7% of revenue) in Q2 2024.
• Net loss for the three months ended June 30, 2025, increased to $2.630 million, up from $1.595 million in Q2 2024.
• Net loss per share for Q2 2025 was $(2.25), compared to $(91.56) in Q2 2024, influenced by reverse stock splits and share issuances.
• Operating expenses increased by 5.4% to $3.361 million for the three months ended June 30, 2025, primarily due to a 40.1% surge in transaction costs related to the pending Merger and Asset Sale.
• Cash and cash equivalents stood at $4.123 million as of June 30, 2025, with a net working capital surplus of approximately $5.7 million.
• Net cash used in operating activities for the six months ended June 30, 2025, was $6.613 million, significantly higher than $3.429 million in the prior year period.
• The company raised $10.9 million in net proceeds from public offerings of common shares and stock warrants in 2025.
• Loans totaling $600,000 were provided to Vyome Therapeutics, Inc. in April and June 2025, recorded as notes receivable.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to significant revenue decline, increased losses, substantial doubt about going concern, and material weaknesses in internal controls. While capital was raised, it appears to be a stop-gap measure for a struggling business facing strong market headwinds from GLP-1 drugs and a critical, but uncertain, merger/asset sale.

Positives

• Successfully raised $10.9 million in net proceeds from public offerings of common shares and stock warrants in 2025, improving liquidity.
• Stockholders approved key proposals related to the Merger with Vyome and the Asset Sale to Biorad, moving these strategic transactions forward.
• Achieved a net working capital surplus of approximately $5.7 million as of June 30, 2025, up from a deficit of $253 thousand at December 31, 2024.

Negatives

• Revenue declined significantly by 36.8% for the three months and 39.8% for the six months ended June 30, 2025, primarily due to competition from GLP-1 pharmaceuticals and reduced sales and marketing efforts.
• Gross profit margin decreased to 48.2% in Q2 2025 from 57.7% in Q2 2024, attributed to lower sales volumes and fixed costs.
• Net loss increased to $2.630 million in Q2 2025 from $1.595 million in Q2 2024.
• Operating expenses rose, driven by a 220.9% increase in transaction costs for the six months ended June 30, 2025, reaching $1.043 million.
• Net cash used in operating activities more than doubled to $6.613 million for the six months ended June 30, 2025, compared to $3.429 million in the prior year.
• The company expects to incur a net loss and negative cash flows from operations for 2025.
• Management anticipates running out of cash during the fourth quarter of 2025 at the current burn rate, raising substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient revenue to offset operating costs and anticipated cash shortfalls within 12 months.
• Failure to complete the pending Merger with Vyome and Asset Sale to Biorad could negatively impact future operations, financial results, and stock price.
• The company will be required to raise additional capital, and there is no assurance that financing will be available on acceptable terms, if at all.
• The medical device industry is characterized by frequent claims and litigation, including product liability claims and intellectual property disputes.
• A proposed class action lawsuit in Canada alleges the Lap-Band gastric banding device causes unacceptably high rates of complications, potentially leading to significant legal liability.
• Material weaknesses in internal control over financial reporting were identified, including insufficient internal accounting resources, lack of management review, ineffective journal entry processes, and IT security risks, which could lead to material misstatements.
• The company's business has been negatively impacted by the introduction of GLP-1 pharmaceuticals, which have taken significant market share in obesity treatments.

Future Outlook

The company's anticipated operations include merging with Vyome and selling certain assets to Biorad, continuing Lap-Band product line growth, introducing Lap-Band 2.0 FLEX, and developing the Diabetes Bloc-Stim Neuromodulation (DBSN) device. Post-merger, the combined company intends to focus on Vyome's immuno-inflammatory assets and identifying opportunities between the Indian innovation corridor and the U.S. market. Management believes it has flexibility to manage expenditures based on cash flows, potentially reducing marketing and product development. However, the company expects to incur a net loss and negative cash flows for 2025 and will require additional capital, with no assurance of availability on acceptable terms. The completion of the Merger and Asset Sale remains subject to conditions, and failure to consummate these transactions could negatively impact future operations.

Management Comments

• "The Company currently does not generate revenue sufficient to offset operating costs and anticipates such shortfalls to continue, primarily due to the introduction of GLP-1 pharmaceuticals, which has taken a significant market share of the medical treatments for obesity."
• "The Company believes that it has the flexibility to manage the growth of its expenditures and operations depending on the amount of available cash flows, which could include reducing expenditures for marketing and product development activities."
• "The Company will be required to raise additional capital, however, there can be no assurance as to whether additional financing will be available on terms acceptable to the Company, if at all."
• "If sufficient funds on acceptable terms are not available when needed, it would have a negative impact on the Company’s financial condition and could force the Company to delay, limit, reduce, or terminate product development or future commercialization efforts or grant rights to develop and market product candidates or testing products that the Company would otherwise plan to develop."
• "Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company’s plans do not alleviate substantial doubt about our ability to continue as a going concern."
• "At the current burn rate, management expects to run out of cash during the fourth quarter of 2025."

Industry Context

The company operates in the weight-loss solutions and medical device industry, which is currently experiencing significant disruption due to the emergence and widespread adoption of GLP-1 pharmaceuticals. These new drug treatments for obesity have taken a substantial market share, directly impacting the demand for traditional medical devices like the Lap-Band system. This shift necessitates a strategic pivot, as evidenced by the company's planned merger with Vyome Therapeutics to enter the immuno-inflammatory assets market and divest its core obesity-related assets.

Comparison to Industry Standards

• The significant revenue decline (36.8% in Q2 2025) and gross profit margin contraction (from 57.7% to 48.2%) indicate underperformance compared to a healthy medical device industry, which typically sees stable or growing revenue and higher gross margins.
• The company's struggle with profitability and cash burn, leading to a 'going concern' warning, contrasts sharply with more established or innovative medical device companies that maintain positive cash flows from operations or have clear paths to profitability.
• The impact of GLP-1 pharmaceuticals on the company's Lap-Band sales highlights a failure to adapt or innovate sufficiently to counter new market entrants, unlike companies that diversify their product portfolios or invest heavily in R&D to maintain competitive edge.
• The planned asset sale for $2.25 million for 'substantially all' assets (excluding cash) suggests a low valuation for its existing obesity business, especially when compared to the market capitalization or asset values of more successful medical device firms.
• The company's reliance on multiple equity raises within a short period ($10.9 million in 2025) and continued 'going concern' doubt indicates a more precarious financial position than industry peers with robust balance sheets or access to less dilutive financing.

Management Changes

Corporate Governance

Legal Proceedings

• A proposed class action lawsuit in Canada, Raymond Edson Marshall v. Allergan Inc., seeks to add ReShape Lifesciences Inc. as a defendant. The plaintiff alleges the Lap-Band gastric banding device causes high rates of complications, including pain, device failure, and permanent injuries, and that the company failed to adequately warn of risks and misrepresented safety/effectiveness.
• Relief sought includes general and special damages for personal injuries, aggravated and punitive damages, statutory damages, recovery of public healthcare costs, and injunctive/declaratory relief.
• The Vancouver Supreme Court granted leave to amend the claim to add the company as a defendant on January 10, 2025, but the company has not been formally served as of the report date.
• Management believes no legal liability is probable or reasonably estimable, and thus there are no implications on the condensed consolidated financial statements for the reported periods.

Related Party Transactions

• Promissory notes totaling $600,000 were issued to Vyome Therapeutics, Inc., the counterparty in the pending merger agreement. These loans are for Vyome's working capital and merger-related expenses, bearing 8.0% interest per annum and due September 30, 2025. If the merger completes, the amounts will be counted as ReShape net cash under the Merger Agreement instead of being repaid.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent and potential future capital raises, as well as the impact of reverse stock splits. The pending merger and asset sale introduce uncertainty but also a potential pivot away from a struggling business. The 'going concern' warning poses a substantial risk to investment value.
• **Employees**: The company's financial struggles and strategic shift (merger/asset sale) could lead to further workforce reductions or changes in roles, as evidenced by the departure of the VP of Regulatory and associated severance costs.
• **Customers**: Current customers of Lap-Band and other obesity solutions may experience changes in product support or availability post-asset sale, as the business will be transferred to Biorad.
• **Suppliers**: The company's financial instability and pending asset sale could impact its ability to meet obligations or continue relationships with suppliers.
• **Creditors**: The 'going concern' warning and need for additional capital raise concerns about the company's ability to service its debts, although recent capital raises have improved short-term liquidity.

Next Steps

• Complete the pending Merger with Vyome Therapeutics, Inc. and the Asset Sale to Ninjour Health International Limited, anticipated to close in Q3 2025.
• The combined company (Vyome Holdings, Inc.) will focus on Vyome's immuno-inflammatory assets and identifying opportunities between the Indian innovation corridor and the U.S. market.
• Continue efforts to grow sales and operations of the Lap-Band product line both domestically and internationally.
• Introduce Lap-Band 2.0 FLEX to the market.
• Continue development of the Diabetes Bloc-Stim Neuromodulation (DBSN) device.
• Explore and capitalize on synergistic opportunities to expand the portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care prior to the merger and sale.
• Implement remediation plans to address identified material weaknesses in internal control over financial reporting.
• Raise additional capital to fund operations, as current cash is projected to run out in Q4 2025.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial decline in revenue (36.8% in Q2 2025), increasing net losses, and a 'going concern' warning, with management explicitly stating they expect to run out of cash by Q4 2025 at the current burn rate. While recent capital raises provide temporary liquidity, they are highly dilutive and do not address the fundamental business decline, exacerbated by competition from GLP-1 pharmaceuticals. The proposed merger and asset sale, while a potential pivot, are not guaranteed and involve divesting the core business at a low valuation. Furthermore, significant material weaknesses in internal controls indicate poor financial management and oversight. The combination of deteriorating financials, existential 'going concern' risk, and operational deficiencies makes this a high-risk investment with a strong likelihood of further value erosion.

Keywords

Weight-loss solutions, Obesity treatment, Medical devices, Lap-Band, Obalon Balloon System, Diabetes Bloc-Stim Neuromodulation, SEC filing, 10-Q, Merger, Asset Sale, Going concern, Capital raise, Financial results, Biotechnology, Healthcare